[Active stents: towards total prevention of restenosis?].
To avoid in-stent restenosis, a new technologic approach with "coated" stents may deliver local cytostatic products (sirolimus, paclitaxel, tacrolimus...). At this time, present clinical studies validate the importance of these active coated stents in sub-groups of patients with diabetes, long lesions, small vessels and proximal left anterior descending coronary lesions.